Even if a metanalysis confirmed the prognostic value of both CD68 and CD163 in HL cases, the main hurdles to overcome are represented by the choice of TAM markers (CD68 vs. CD163 vs. CD68/CD163 double-positive), the different cutoffs used to define a high TAM expression and the different monoclonal antibodies used for IHC (KP-1 or PGM-1 for CD68 evaluation) [101,131]. The gene discussed is CD163; the disease is Hodgkins lymphoma.